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ABSTRACT: We present the cellular quantitative structure−activity relationship (cell-QSAR) concept that adapts ligand-based
and receptor-based 3D-QSAR methods for use with cell-level activities. The unknown intracellular drug disposition is accounted
for by the disposition function (DF), a model-based, nonlinear function of a drug’s lipophilicity, acidity, and other properties. We
conceptually combined the DF with our multispecies, multimode version of the frequently used ligand-based comparative
molecular ﬁeld analysis (CoMFA) method, forming a single correlation function for ﬁtting the cell-level activities. The resulting
cell-QSAR model was applied to the Selwood data on ﬁlaricidal activities of antimycin analogues. Their molecules are ﬂexible,
ionize under physiologic conditions, form diﬀerent intramolecular H-bonds for neutral and ionized species, and cross several
membranes to reach unknown receptors. The calibrated cell-QSAR model is signiﬁcantly more predictive than other models
lacking the disposition part and provides valuable structure optimization clues by factorizing the cell-level activity of each
compound into the contributions of the receptor binding and disposition.
■ INTRODUCTION
Conceptual methods for the correlation of binding aﬃnities
with drug structure (3D-QSARs) are vital to the drug
development process. The approaches include receptor-based
methods,
1 e.g., free energy perturbation,
2 the linear response
method,
3−5 and the mining minima approach,
6−9 and ligand-
based methods for unknown receptors, e.g., comparative
molecular ﬁeld analysis (CoMFA).
10 The methods have been
developed and perform satisfactorily for the binding data
measured with isolated macromolecules. Unfortunately, binding
aﬃnities for isolated macromolecules are often unavailable
because the receptors have not yet been identiﬁed, cannot be
isolated without denaturation or dissociation, or do not work in
aqueous solutions. In such situations, more complex assays are
used, deploying receptors reconstituted in lipid vesicles as the
simplest system or utilizing intact cells, tissues, organs, or
organisms.
The eﬀective concentrations of the drugs in the receptor
surroundings vary among the studied compounds because of
interactions with nonreceptor assay constituents. Drug
disposition has often been neglected in modeling the
bioactivities measured in complex systems. At best, the 1-
octanol/water partition coeﬃcients and their squares,
11 and
sometimes the dissociation constants,
12 as properties aﬀecting
the disposition, have been included in simpliﬁed linear forms.
In many cell-level studies, 3D-QSAR methods have been
applied without any correction for ligand disposition or
empirical models with various descriptors have been deployed.
Here, we propose a straightforward solution to the problem of
QSAR modeling of cell-level data: extend the proven 3D-QSAR
methods by accounting for the varying ligand disposition in the
receptor surroundings using the disposition function (DF). The
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equation combining the 3D-QSAR expression and the DF,
whereby the coeﬃcients in both parts can be optimized either
simultaneously or separately if the uptake data are available.
The exact form of the correlation equation depends on the
kinetics of the processes underlying the drug eﬀects and on the
complexity of studied compounds (common skeleton, similarity
of substituents, ability to ionize and form tautomers), as
discussed in the Methods.
The DF describes the kinetics of drug disposition and relates
the dose or the initial concentration to the concentration in the
receptor surroundings (see eq 2 in the Methods). The ﬁrst DF
forms were peak-shaped dependencies, on logarithmic scales, of
the drug concentration inside the receptor compartment, which
was separated from the dosing compartment by a few bilayers,
on lipophilicity (the reference partition coeﬃcient).
13−16 These
dependencies represented the basis of the ﬁrst QSAR
techniques, such as the Hansch approach
13 and related
m e t h o d s .S u b s e q u e n t l y ,o t h e rp a r a m e t e r s ,i n c l u d i n gt h e
ionization constant,
17 the exposure time, the metabolic rate
parameters,
18 the ratio of the partition coeﬃcients in alkane/
water and 1-octanol/water systems,
19−22 and the polar surface
area
23,24 as descriptors of H-bonding ability, the partition
coeﬃcient between phosphatidylcholine headgroups and
hexadecane as a predictor of bilayer localization and
partitioning,
25 the membrane-interaction QSAR parameter-
s,
26,27the polarizability,
28the cross-sectional area of the mole-
cule,
29 and numerous others, were added. The DF functional
forms developed from the parabolic,
13 bilinear,
15 nonequili-
brium,
30 equilibrium,
17 and mixed models to the pseudoequili-
brium DF.
31,32 Some of these DFs predicted reliably outside the
used property ranges, in contrast to empirical models.
33
The DF can also be calibrated independently using the data
on cellular uptake and disposition, which are obtained by
various experimental approaches. High-content screening
techniques provide more detailed information than classical
uptake experiments,
34 as demonstrated for the disposition of a
small library of lipophilic, ﬂuorescent compounds in living
HeLa cells.
35 Structure-dependent phenomena, such as active
Table 1. Structures and Properties of Antimycin Analogues
compd no. R1 R2 log P
a pKa
b log K
c log DF
c log(1/EC50)
d
1 3-NHCHO NHC14H29 7.491 7.88 1.181 4.150 5.155
2
e 3-NHCHO NHC6H3-3-Cl-4-(OC6H4-4-Cl) 5.955 7.21 2.307 3.438 5.620
3 5-NO2 NHC6H3-3-Cl-4-(OC6H4-4-Cl) 6.944 5.15 1.710 5.476 7.398
4 5-SCH3 NHC6H3-3-Cl-4-(OC6H4-4-Cl) 7.402 8.00 2.290 4.086 6.319
5 5-SOCH3 NHC6H3-3-Cl-4-(OC6H4-4-Cl) 5.722 6.80 1.843 3.535 5.125
6 3-NO2 NHC6H3-3-Cl-4-(OC6H4-4-Cl) 6.944 4.60 1.668 5.548 6.824
7 5-CN NHC6H3-3-Cl-4-(OC6H4-4-Cl) 6.698 5.66 2.534 5.225 7.839
8 5-NO2 NHC6H4-4-(OC6H4-4-CF3) 6.541 5.15 1.483 5.397 7.022
9 3-SCH3 NHC6H3-3-Cl-4-(OC6H4-4-Cl) 7.402 7.47 1.931 4.292 6.420
10 5-SO2CH3 NHC6H3-3-Cl-4-(OC6H4-4-Cl) 5.731 6.11 1.681 4.166 6.000
11
e 5-NO2 NHC6H4-4-(OC6H5) 5.658 5.31 1.450 4.818 6.097
12 5-NO2 NHC6H3-3-Cl-4-(COC6H4-4-Cl) 6.264 5.37 1.803 5.184 7.131
13 5-NO2 NHC6H4-4-(OC6H3-2-Cl-4-NO2) 5.884 5.20 1.936 5.067 6.921
14 5-NO2 NHC6H3-3-Cl-4-(OC6H4-4-OCH3) 6.150 5.11 1.839 5.271 6.770
15 3-SO2CH3 NHC6H3-3-Cl-4-(OC6H4-4-Cl) 5.731 5.10 1.433 5.034 6.301
16 5-NO2 NHC6H3-3-Cl-4-(SC6H4-4-Cl) 7.476 5.25 1.554 5.504 7.357
17
e 3-NHCHO NHC6H13 3.259 7.88 4.018 0.430 <5.000
18 3-NHCHO NHC8H17 4.317 7.88 4.091 1.488 5.585
19
f 3-NHCOCH3 NHC14H29 7.468 7.88 1.181 4.143 5.097
20
e 5-NO2 NHC14H29 8.648 5.83 1.016 5.406 6.893
21 3-NO2 NHC14H29 8.648 5.28 1.293 5.522 6.818
22 3-NO2-5-Cl NHC14H29 9.419 4.68 1.684 5.564 7.362
23 5-NO2 NHC6H4-4-C(CH3)3 5.386 5.55 1.659 4.369 6.229
24
e 5-NO2 NHC12H25 7.590 5.83 1.647 5.361 7.409
25 3-NO2 NHC16H33 9.706 5.28 0.555 5.524 5.959
26 5-NO2 NHC6H3-3-Cl-4-(NH-C6H4-4-Cl) 6.900 5.12 0.968 5.477 6.432
27 5-NO2 NHC6H4-4-(OC6H4-3-CF3) 6.541 5.16 1.675 5.394 7.027
28 5-NO2 NHC6H3-3-Cl-4-(NHC6H4-4-SCF3) 7.899 5.04 1.711 5.541 7.553
29 5-NO2 NH-3-Cl-4-(3-CF3C6H4O)C6H3 7.114 5.06 1.872 5.510 7.071
30
e 5-NO2 NHC6H4-4-(CH(OH)C6H5) 3.870 5.42 1.197 3.015 <5.000
31
f 5-NO2 C6H4-4-Cl 4.329 6.73 0.777 2.221 6.481
aClogP-predicted 1-octanol/water partition coeﬃcient P.
bSPARC-predicted acidity of the phenolic hydroxyl.
cAﬃnities and disposition function
values predicted from the DF-MSMM CoMFA model.
dMeasured antiﬁlarial activities (molar EC50).
36,52 eTest set compounds.
fCompounds
excluded before analysis because of singularity.
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process.
The additional eﬀort to obtain and ﬁt the disposition data
can be spared in situations when the disposition is not
complicated by structure-dependent phenomena. Then the DF
depends on drug properties characterizing the bilayer transport
and accumulation, nonspeciﬁc protein binding, hydrolysis, and
other nonenzymatic reactions. An appropriate DF can be
selected from the armoire of available models and can be
calibrated simultaneously with the 3D-QSAR model using the
cell-level data. This approach is demonstrated here using the
Selwood data
36 on ﬁlaricidal activities of analogues of antimycin
A, which inhibits mitochondrial electron transport and
oxidative phosphorylation
37 and induces apoptosis.
38 These
data are regarded as diﬃcult to model and are frequently used
to validate QSAR methods on the basis of variable selection.
The descriptive ability of the generated models did not exceed
60−80% of the explained variance,
36,39−47 so there is space for
improvement.
To the best of our knowledge, this cell-QSAR study
represents the ﬁrst attempt at the QSAR modeling of drug
eﬀects in complex systems, where both drug−receptor
interactions and drug disposition signiﬁcantly vary among
studied compounds and both are conceptually treated using a
common correlation equation.
■ RESULTS AND DISCUSSION
Studied Antimycin A Analogues. The studied com-
pounds, listed in Table 1, have varying substituents, R1, on the
phenol ring and large lipophilic substructures, R2, which replace
a complex dilactone moiety of the parent compound. The
compounds can be formally divided into three groups: two-ring
analogues (23 and 31), three-ring analogues (2−16 and 26−
30), and alkyl-chain analogues (1, 17−22, 24, and 25). The
salicylamide moiety, present in all compounds except 31,
exhibits a peculiar intramolecular H-bonding.
48,49 Two types of
intramolecular H-bonds are formed, depending upon ionization
of the hydroxyl (Figure 1).
The hydroxyl pKa values (Table 1) of the studied antimycins
were estimated by the SPARC method,
50 which seems to take
the intramolecular H-bond into account. The magnitude of the
pKa values (range 4.6−8.0) is determined mainly by the
electron-withdrawing ability of the R1 substituents on the
phenol ring, with the R2 substituents exhibiting a slighter
inﬂuence. Under neutral conditions, the compounds are
present in the aqueous solution as a mixture of ionized and
nonionized species, with the balance shifted toward the ionized
species for most compounds, except compounds 1, 2, 4, 9, and
17−19 having pKa > 7. Formation of tautomers and carbonyl
hydrates was negligible, according to the SPARC estimates;
otherwise, they would be included in the model in the same
way as ionization. Table 1 also contains the activities spanning
almost 3 orders of magnitude and the 1-octanol/water partition
coeﬃcients P (ClogP estimates
51 for neutral molecules).
Antimycin A is a known inhibitor of oxidative phosphor-
ylation.
37 Therefore, we examined whether the Selwood data
could be explained by our two-decade-old, conceptual QSAR
model for uncouplers.
34 The model describes isoeﬀective
concentrations eliciting a given degree of uncoupling as a
nonlinear function containing lipophilicity (P) and acidity
(pKa). Although the surface generated by the ﬁt to the data was
reminiscent of the expected shape,
34 the deviations of individual
compounds were too large to consider the ﬁt satisfactory. We
hypothesized that the deviations were caused by structure-
speciﬁc interactions with an unknown receptor; therefore, we
decided to deploy a ligand-based 3D-QSAR method.
Setup of the Cell-QSAR Model. The cell-QSAR
correlation equation for the simplest drug eﬀect scenario
consists of the product of the drug−receptor association
constant K and the DF (eq 3 in the Methods). The receptor is
unknown in this case, so K was expressed using one of the
popular ligand-based methods, CoMFA.
10 The antimycin
analogues ionize to diﬀerent degrees and are ﬂexible; therefore,
we applied our multispecies (MS), multimode (MM)
modiﬁcation of CoMFA.
53 The pseudoequilibrium form of
the DF (eq 10 in the Methods),
32 treating absorption as an
instantaneous process, was chosen, because no lag phase was
observed in the time course of toxicity.
36,52 An additional
reason for selecting this DF form was the ability of the
underlying model
32 to handle speciation of the ligands.
Ligand Superposition. Pharmacophores obtained for all
species using the Galahad procedure,
54,55 which performs
ﬂexible superposition based on the active analogue approach,
56
indicated that the salicylamide moieties are closely super-
imposed in all cases. This outcome is consistent with the
apparent importance of this moiety for inhibition: an analogue
capable of H-bond formation (Figure 1) inhibited the
cytochrome bc1 complex activity in submitochondrial particles
much stronger than a similar analogue lacking this ability.
57
A rigid compound that preferably exhibits a high activity
would be very useful for guiding the superposition of the
ligands. Unfortunately, there is no truly rigid analogue available
in the studied series. The three-ring compounds contain more
rigid aromatic rings than other compounds, so we selected the
most active compound in this group and in the entire series (7)
as the template. Because the pharmacophore-generating
procedure did not provide clues about the conformation of
the lipophilic fragments connected to the salicylamide ring, we
used the low-energy conformations of compound 7 as the
assumed bound conformations. This step is associated with the
risk that the overall spatial organization of the binding site
model may not completely correspond to that of the actual
receptor. While the binding points will be positioned
appropriately around individual rigid rings of the template,
the relative positions of the individual groups of points
surrounding the rigid fragments may diﬀer from those of the
actual receptor because of possible fragment rotations. This
drawback would not aﬀect the predictive ability of the model
for compounds which can adopt the template conformation
without signiﬁcant conformational strain.
The conformational space of compound 7 is characterized by
four torsions (Figure 2). Conformational analysis identiﬁed the
minimum-energy conformations for the H-bonded forms of
both neutral and ionized molecules (Figure 1). The common
minimum conformations of ionized and neutral species without
Figure 1. Conformational switching of an intramolecular H-bond in
the salicylamide ring of antimycin derivatives upon ionization.
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possibility that the hydroxyl and the amide groups would
interact with the receptor instead of forming the intramolecular
bond. Two skeleton conformations appear for each of the two
species: one closed via the intramolecular H-bond and one open
without the H-bond. The conformations are summarized in
Table 2.
It has long been recognized that ﬂipping of symmetrical rings
with asymmetrically placed substituents results in similar but
distinct bound geometries. If the receptor structure is unknown,
preferred geometries cannot be selected a priori and all
geometries should be considered in model building.
58−64 A
t o t a lo f1 6o f3 1s t u d i e dc o m p o u n d s( T a b l e1 )h a v e
substituents in meta-positions on either the middle ring (2−
7, 9, 10, 12, 14−16, 26, and 28) or the third ring (13 and 27).
For these compounds, rotation of the asymmetrically
substituted ring by 180° led to doubling of the existing two
modes. Compound 29 with two asymmetrically substituted
rings is represented by eight modes.
The process of creating individual superpositions is
illustrated in Figure 3. The four basic templates of compound
7 were superimposed by the atom ﬁt method in Sybyl (Figure
3b) to ensure the best overlap of the salicylamide moieties, as
suggested by the generated pharmacophore. All other
molecules were superimposed on the templates using the
FlexS procedure
65 (Figure 3c,d).
DF-MSMM CoMFA Analysis. The analysis is based on the
correlation equation obtained by taking the logarithm of eq 3
(X = 0.5 because the EC50 values are modeled), with the
association constant K expressed by eq 9, and the DF given by
eq 10 (the exposure time t = constant) combined with eqs 11
and 12. For both the receptor-binding and disposition parts,
ionization is included and the coeﬃcients are optimized
simultaneously.
Optimization examines two forms of the DF, for the aqueous
phases (shown in eq 10) and membranes. If the receptors are
localized in a membrane and the compounds bind to them
from the hydrocarbon core of the bilayer, eq 10 needs to be
multiplied by Pβ (P is the reference partition coeﬃcient and β is
the Collander coeﬃcient, which is one of the optimized
regression coeﬃcients). The water and membrane variants of
eq 10 are initially used in fully expanded form: each of the
coeﬃcients A−D is replaced by eqs 11 and 12. The
optimization proceeds with gradual forward selection of
energies in relevant grid points in the CoMFA part, which is
done separately for the two forms of the DF. The better DF is
selected on the basis of the statistical criteria and further
optimized by omitting the parameters with higher standard
deviations, if the elimination does not cause a signiﬁcant
decrease in statistical criteria. One, or sometimes both, of the
coeﬃcients C and D, describing lipophilicity-dependent and
lipophilicity-independent elimination, can frequently be
omitted. In each pair of coeﬃcients A−D (eq 11), the term
for one species may or may not be signiﬁcant.
The combinatorial search for the best DF-MSMM CoMFA
model was extensive for three reasons: many possible
combinations of relevant grid points need to be examined,
the DF can have multiple functional forms, and many sets of
the initial estimates of coeﬃcients need to be tested to avoid
trapping in local minima. The best model was selected on the
basis of the r2 and q2 (for the leave-one-out cross-validation in
the training set, used to eliminate unstable models) values and
Figure 2. Four torsions of compound 7 (Table 1) characterizing the
conformations of three-ring analogues displayed in red color. They are
Φ1 (C3−C4−C11−O12), Φ2 (C11−N13−C15−C20), Φ3 (C17−
C18−O22−C23), and Φ4 (C18−O22−C23−C28).
Table 2. Superposition Templates Based on the Most Active Compound 7 (Table 1)
torsion
c (deg)
template no. species
a conformation
b intramolecular H-bond Φ1 Φ2 Φ3 Φ4
1 neutral closed OH···OC 4.1 2.8 93.8 178.5
2 neutral open none 137.7 −15.7 208.3 225.4
3 ionized closed NH···O− 180.6 0.8 98.4 174.7
4 ionized open none 137.7 −15.7 208.3 225.4
aSee Figure 1.
b“Closed” and “open” refer to the intramolecular H-bond being present and absent, respectively.
cSee Figure 2.
Figure 3. Superposition procedure: (a) four basic templates of
compound 7, generated by conformational analysis and numbered as
in Table 2; (b) superposition of the four basic templates; (c)
superpositions of all compounds (Table 1) to the four basic templates
in respective species and conformations, numbered as in row a; (d)
ﬁnal superpositions, enriched by ﬂipping the benzene rings by 180° for
the MSMM situation (I; 200 molecules = 31 compounds × 2 species ×
2 skeleton conformations × 1, 2, or 4 ring-ﬂipping conformations), the
MM situation (II; 100 molecules created as in situation I but with 1
species), and the standard one-mode situation (III; 31 molecules).
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deviations. For illustration, there were 65021 models with r2 ≥
0.6, 11142 models with r2 ≥ 0.8 and q2 ≥ 0.6, and 3752 models
with r2 ≥ 0.9 and q2 ≥ 0.7, of which 25 models had less than 11
coeﬃcients, each with smaller than 60% standard deviation.
The best DF-MSMM CoMFA model contained the DF for
the compounds interacting with the receptors in a membrane,
with metabolism that was either insigniﬁcant or invariant for
the studied compounds (C = 0 and D = 0), and ﬁve required
CoMFA grid points. The ﬁnal, pruned correlation equation,
resulting from eq 3 (X = 0.5), with the association constant K
expressed by eq 9 (the subscript i was omitted for fractions f),
and the DF given by eqs 10−12, was
∑∑ β =+
−+ +
∑
β
==
+
=
⎛
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The ﬁrst term is an MSMM CoMFA expression for the
receptor binding (log K), and the remaining terms describe
disposition (log DF). The fractions of ionized and nonionized
molecules, f1 and f 2, respectively, include the pKa values and the
optimized pH value as shown in eq 12 and are identical in both
receptor-binding and disposition terms. The microscopic
association constant Kij for each of the m considered modes
is represented by a k-summand. Each of the k-summands
contains ﬁve identical adjustable coeﬃcients, C1−C5, which, for
the selected grid points (coordinates in Table 3), multiply the
energies Xijkl for the given modes. The addition of multiple
modes does not increase the number of optimized coeﬃcients;
it only changes the form of the correlation equation by
increasing the number of k-summands.
Nonlinear regression analysis resulting in eq 1 provided the
following outcome for the best DF-MSMM model. For the
receptor-binding expression, the results are summarized in
Table 3. The optimal values of the disposition-describing
coeﬃcients for the DF were A1 = (7.142 ± 2.213) × 10−5, A2 =
(2.636 ± 1.254) × 10−6, B1 = (9.989 ± 4.233) × 102, and pH
7.56 ± 0.32. The optimization of the Collander coeﬃcient β
and the coeﬃcient C0 did not lead to a suﬃcient improvement,
so their values were ﬁxed as β = 1 and C0 = 0. The description
statistics, calculated for the training set, consists of the sum of
squares of errors (SSE), where the error is the diﬀerence
between calculated and experimental values, and the squared
correlation coeﬃcient (the coeﬃcient of determination, equal
to the percentage of explained variance) r2 =1− SSE/SYY,
where SYY is the sum of squares of deviations of the
experimental log K values from their average. The prediction
statistics contains similar indices calculated for the test set that
was not used in the development of the model: predictive sum
of squares of deviations between predicted and experimental
values (PRESS) and the squared correlation coeﬃcient q2 =1−
PRESS/SYY. Table 4 summarizes the descriptive (SSE and r2
for the training set) and predictive (q2 and PRESS for the test
set) statistical criteria for the DF-MSMM CoMFA model (1)
and for the reduced models (2−13). For comparison, the
random scrambling of bioactivities (50 runs) produced no
signiﬁcant correlations, with the average values of SSE = 11.12
and r2 = 0.250. Optimized eq 1 also provides the aﬃnity (log
K) and disposition (log DF) components of bioactivity (Table
1). A test set (Table 1, compounds 2, 11, 17, 20, 24, and 30)
covering the entire range of biological activities was selected
before optimization. The use of multiple test sets, which would
be a preferred way to examine the predictive abilities of the
model, was precluded by the extent of the optimization
procedure. For compounds 17 and 30 with semiquantitative
activities, the q2 and PRESS values (Table 4) were calculated
using the upper limits, i.e., log(1/EC50) = 5. Because only the
DF-MSMS CoMFA model correctly predicted log(1/EC50)<5
(Figure 4b), the predictive abilities are probably under-
estimated for the DF-MSMS CoMFA model and overestimated
for all other models.
Table 4 demonstrates that all features used in the DF-
MSMM CoMFA model are necessary for a good prediction.
Omission of the disposition leads to a decline in predictive
abilities (PRESS and q2), even if multiple species and/or modes
are considered (models 2 and 3). The decline is more severe
for standard, one-mode CoMFA models (4−13), including
those with the averaged multiple modes (models 6, 9, and 12)
and even for the prevalent bound species and modes (model
13), which were selected by DF-MSMM CoMFA model 1. This
fact indicates that the one-mode QSAR solution may not exist.
Although only this indirect, model-based indication is available
for the studied case, multiple modes were experimentally
proven to occur in many ligand−macromolecule complexes
(see the references in ref 57). Interestingly, the descriptive
abilities (SSE and r2) were great in all cases. This may, in part,
explain the use of 3D-QSAR methods without any description
of disposition for cell-level activities.
It is worth mentioning that an exhaustive examination of
modes and species for each compound in a standard CoMFA
analysis, seeking a one-mode solution, is technically not
feasible. The 23 compounds of the training set, each present
in two species and two conformations (for simplicity, the ring-
ﬂipping conformations are omitted), would require 4
23 analyses
or about 2.2 million CPU years, if a single one-mode analysis
only lasts 1 s. Therefore, the MSMM approach, performing an
extensive, albeit not exhaustive search lasting several weeks on a
few processors, compares favorably.
The calculated bioactivities for the training set and the
predictions for the test set compounds are compared with
experimental values in parts a and b, respectively, of Figure 4.
The use of multiple species and modes and, especially, of the
DF clearly improves predictivity (PRESS and q2). Descriptive
statistical indices for calibration display a similar trend, except
for the excellent SSE and r2 values for the standard, one-mode
CoMFA model, utilizing the full set of energies. The standard
model, however, did not conﬁrm its calibration quality in the
prediction exercise (Figure 4b).
3D-QSAR Contour Map. The steric and electrostatic
contours for the DF-MSMM CoMFA model with various
Table 3. Characterization of the Receptor-Binding Part of
the DF-MSMM CoMFA Model (Eq 1)
coordinates (Å)
b
coeﬃcient value
a xy z energy
c
C1 0.538 ± 0.247 12.66 6.83 4.780 S
C2 −1.931 ± 0.711 6.668 10.836 −5.218 S
C3 −0.245 ± 0.108 2.668 6.836 −3.218 E
C4 −6.657 ± 2.873 4.668 16.863 −5.218 S
C5 0.116 ± 0.043 −3.330 14.836 −7.2184 E
aRegression coeﬃcients.
bGrid point coordinates.
cEnergy types: S,
steric, E, electrostatic.
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superposition (Figure 3d, situation I) are displayed in Figure 5,
along with representative ligand conformations. The contour
map shows that the binding site model is deﬁned by a sterically
favorable region near the salicylamide ring, two sterically
unfavorable regions in the midsection of the binding site, an
electronegative-favoring region near the second ring of two- or
three-ring compounds, and an electropositive-favoring region at
the lipophilic end of the molecules. The absence of electrostatic
regions around the salicylamide ring may result from small
diﬀerences among the studied compounds in this substructure.
The binding conformation in which the bulky chlorine atom
in the second ring is closer to the salicylamide OH group and
far from a sterically unfavorable region (Figure 5a) is preferred
in 11 out of 15 compounds. Consequenty, the ring-ﬂipped
conformation (Figure 5b) is not populated. Compounds with
lipophilic alkyl groups tend to have a wide range of activities
depending on the length of the alkyl chains. Compounds 17
and 18 (Figure 5c) with six and eight methylene groups,
respectively, bind in an extended conformation and show the
highest predicted binding aﬃnities (Table 1, log K > 4),
indicating the optimal chain length for binding. On the other
hand, compounds with 12−14 methylene groups (Table 1, 1,
19−22) bind in a packed conformation (Figure 5d) that results
in low aﬃnities (Table 1, log K < 1.7), probably because the
folded chain protrudes into the sterically unfavorable regions.
For the same reason, the aﬃnity of compound 25 with 16
methylene groups exhibits a further drop (log K ≈ 0.5). This
reasoning could also apply to compound 23 showing only
average aﬃnity (log K ≈ 1.7), although its 4-tert-butylphenyl
ring is similar in length to the optimal n-hexyl chain in the
extended conformation (compound 17) but is much bulkier.
The red electronegative-favoring region in the midsection of
the binding site improves the aﬃnity (log K)o f1 5o f3 1
compounds with an electronegative chlorine atom in the
second ring, even though their overall activities diﬀer
signiﬁcantly because of varying disposition. This interaction
also causes the compounds with the electronegative oxygen
(2−11, 13−15, 27, 29) or carbonyl (12) linkers between the
second and third rings to have a higher binding aﬃnity than
compounds with other linkers (16, 26, 30).
Two compounds, 19 and 31, were excluded from
optimization before its start because of singularities caused by
molecular parts protruding into subspaces which were not
Table 4. Statistical Indices Characterizing CoMFA Models of Varying Complexity
a
statistical indices
CoMFA model descriptive predictive
no. species mode no. of coeﬃcients SSE r2 PRESS q2
1 DF-MS MM 5 + 5 0.902 0.923 1.356 0.815
2 MS MM 11 2.336 0.801 3.161 0.569
3 SS: major
b MM 11 2.476 0.789 2.995 0.592
4 SS: neutral SM: closed 5 (3568)
c 0.154 0.987 6.410 0.126
5 SS: neutral SM: open 5 (3563) 0.361 0.969 6.070 0.173
6 SS: neutral MM: average
d 5 (564) 0.400 0.966 6.498 0.114
7 SS: ionized SM: closed 5 (3569) 0.155 0.987 6.686 0.089
8 SS: ionized SM: open 5 (3584) 0.196 0.983 5.411 0.262
9 SS: ionized MM: average
d 5 (572) 0.580 0.951 6.228 0.151
10 SS: major
b SM: closed 5 (3570) 0.154 0.987 6.785 0.075
11 SS: major
b SM: open 5 (3583) 0.325 0.972 4.818 0.343
12 SS: major
b MM: average
d 5 (534) 0.064 0.995 5.897 0.139
13 SS: bound
e SM: bound
e 5 (3581) 0.403 0.966 4.455 0.393
aThe models diﬀer in the use of disposition function (DF), multiple or single species (MS or SS), and multiple or single modes (MM or SM).
bPrevailing species in aqueous solution used for each compound.
cNumber of latent variables shown, with the number of all energies given in
parentheses.
dThe energies of all considered modes are averaged and analyzed by standard, one-mode CoMFA.
ePrevalent bound species and mode
as determined by the DF-MSMM CoMFA model used for each compound.
Figure 4. Calculated and predicted activities plotted against experimental data for the training set (a) and test set (b), generated with the DF-
MSMM (black), MSMM (blue), SSMM (red), and standard (green) CoMFA models (models 1−3 and 11 in Table 4, respectively). In plot b, the
two experimental values of log(1/EC50) = 5 are actually <5 (Table 1, compounds 17 and 30), as indicated by the arrows.
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compound 19 is caused by the 3-acetamide group in the
salicylamide ring, which reaches a spot in the vicinity of the
sterically attractive region (Figure 5d). The singular region may
be an open, water-ﬁlled space with no eﬀect on aﬃnity because
the prediction for compound 19 by the DF-MSMM model (log
K + log DF = 5.324, Table 1) is close to the experimental
log(1/EC50) = 5.097. Compound 31 lacks an amine linker
between its rings, and therefore, its molecule extends into
uncharted space. Compound 31 has a much lower predicted
activity (log K + log DF = 2.998) than the actual measured
log(1/EC50) = 6.461. This diﬀerence indicates that there may
be an attractive spot in the midsection of the binding site which
the model does not capture because of the lack of molecules
occupying this region.
Prevalences of Bound Species and Modes. The
prevalences, given by the Boltzmann distribution shown in eq
8 in the Methods, cannot be guessed a priori because they are
one of the outcomes of optimization. The prevalences for the
DF-MSMM CoMFA model (eq 8), with individual Kijk values
calculated as the decadic terms in eq 1 with optimized values of
the coeﬃcients Cl, are shown in detail in the Supporting
Information and summarized here. A total of 16 of 31
compounds (1, 2, 8, 10, 11, 13, 15−18, 23, 25, 27, 28, 30, 31)
bind predominantly in the closed conformation, maintaining
the intramolecular H-bond (Figure 1). The remaining
compounds bind in the open conformation, exposing the
salicylamide’s polar groups, with at least 50% prevalences.
Compounds 15, 17, 18, and 25 bind 100% in the closed
conformation, while compound 20 binds 100% in the open
conformation.
Most compounds prefer to bind as ionized species. The
exceptions are compounds 2, 4, 9, 17, and 18, for which the
neutral species bind with 74%, 53%, 58%, 100%, and 100%
prevalences, respectively. Figure 6 indicates that the species
distributions of bound and free molecules are quite similar for
most compounds. For neutral species, most compounds have
both the fraction in water and binding prevalence less than
10%. For ionized species, most compounds have the fraction in
water and binding prevalence as high as 90%. About a quarter
Figure 5. Contour maps of the DF-MSMM CoMFA model with embedded superposition of all 200 molecules to indicate the applicability space.
Green and yellow contours indicate regions that are sterically favorable and unfavorable, respectively. Blue regions favor electropositive groups, and
red regions favor electronegative groups. The following ligands are presented in ball and stick models: (a) compound 2 (Table 1) binding in ionized
and open conformation, (b) compound 2 binding in neutral and closed conformation, showing the clash of the 3-Cl in the second ring with one of
the sterically unfavorable regions, (c) compound 18 with a shorter alkyl chain, one of the strongest binders, (d) compound 19 with the 3-acetamide
group in the salicylamide ring occupying a sterically favorable region, showing clashes of the long chain with one of the sterically unfavorable regions.
Figure 6. Speciation of free and bound molecules according to the DF-
MSMM CoMFA model. Neutral and ionized species are shown in blue
and red, respectively, as the compound number (Table 1).
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signiﬁcant diﬀerences between the fractions in water and
binding prevalences.
The predominant binding species and binding conformations
are to a large extent aﬀected by the substituents in the
salicylamide ring. Strong electron-withdrawing groups promote
ionization and also contribute to higher activity: only 3 (4, 9,
31) out of 24 compounds with log(1/EC50) > 6 have pKa > 6.5
(Table 1). However, lipophilic moieties including alkyl chains
and two or three ring systems also aﬀect the binding as well as
disposition, so the structure−activity relationships are complex.
Binding of Alkyl-Chain Analogues. The strongest binders,
compounds 17 and 18 (Table 1, log K > 4) with a 3-
formylamino group in the salicylamide ring predominantly bind
as neutral species in the closed conformation. The shorter alkyl
chains may allow suﬃcient conformational freedom for these
two compounds to make the best possible interactions in the
binding site, leading to high binding aﬃnities. Long-chain
analogues (compounds 19−22 and 24, Table 1) predominantly
bind in ionized open conformations or sometimes in ionized
closed conformations, as seen for compounds 1 and 25. All
long-chain analogues exhibit low to average binding aﬃnity,
possibly because of steric clashes of long chains in packed
conformations (Figure 5d) with the sterically unfavorable
regions in the midsection of the binding site.
Binding of Two- and Three-Ring Analogues. Compounds
with a 2-NO2 or 5-NO2 group in the salicylamide ring bind
predominantly as ionized species, either in open or closed
conformations, depending upon the presence of a 3-Cl
substituent in the second ring (the absence of which seems
to be compensated by the presence of a 2-Cl or 4-CF3
substituent in the third ring). Compounds 3, 6, 12, 14, 26,
28, and 29 with a 3-Cl substituent in the second ring mainly
bind in the open conformation, although compounds 12 and
29 bind about equally in the closed conformation as well, and
compound 28 shows slightly higher preference for the closed
conformation. This variation is possibly aﬀected by the
presence of a carbonyl linker group between the second and
third rings in compound 12 and 4-SCF3 and 3-CF3 groups in
the third ring of compounds 28 and 29,r e s p e c t i v e l y .
Compounds without a 3-Cl substituent in the second ring (8,
11, 13, 23, 27, and 30) bind predominantly as ionized species
and show higher preference for the closed conformation. The
absence of steric hindrance by a chlorine substituent in the
second ring allows these compounds to assume the preferred
closed conformation with an intramolecular H-bond between
the amide NH and phenoxide ion. Compound 16 (with a 5-
NO2 group in the ﬁrst ring and a 3-Cl substituent in the second
ring) prefers to bind in the closed conformation, possibly
because of the presence of a thioether linkage between the
second and third rings, resulting in a longer linker. The most
active in this series, compound 7 with a 5-CN substituent in the
salicylamide ring, binds predominantly as an ionized species in
the open conformation.
Inﬂuence of Disposition. The disposition of antimycins in
female worms of Dipetalonema viteae after 120 h of exposure
52
can be visualized for individual compounds as the diﬀerence
between the experimental log(1/EC50) values and the log K
values (Table 1) calculated from the aﬃnity part of the DF-
MSMM CoMFA model (eq 1). These values are plotted as a
function of the drugs’ lipophilicity (log P) and acidity (pKa)i n
Figure 7, along with the surface given by the disposition part of
the DF-MSMM CoMFA model (eq 1) with optimized
coeﬃcients. The shape of log DF(P,Ka)i sr e m a r k a b l y
nonlinear: it is essentially composed of interconnected planes
positioned at varying angles. No further curvatures are
expected, according to the model, as the planes extend in all
four directions to the limit property values, so this conceptual
function safely predicts outside of the property ranges.
33
Disposition signiﬁcantly modulates the bioactivity of antimycins
by ∼5 log(1/EC50) units. Using the correct form of the DF for
the correlations is essential, because its peculiar shape (Figure
7) is diﬃcult to emulate by polynomials, which are too ﬂexible
to approximate the planar areas.
33
The resulting ﬁt (eq 1, Table 3 and accompanying text) can
be interpreted as follows. The variation in disposition is caused
by pseudoequilibrium partitioning of ionizable compounds.
The hypothetical receptors are localized in a membrane, with
the drugs accessing the binding site (the CoMFA model in
Figure 5) from within the bilayer. The optimized coeﬃcients
are associated with the processes that determine drug
disposition: A, with bilayer accumulation and nonspeciﬁc
protein binding; B, with accumulation in aqueous phases,
with subscripts 1 and 2 indicating the relatedness to the
nonionized and ionized species, respectively. The coeﬃcient B2
was not necessary for a good ﬁt, indicating that accumulation of
ionized molecules in the aqueous compartments did not cause
signiﬁcant variation in overall disposition. The exponent,
coming from eq 10 and containing coeﬃcients C and D
describing metabolism, need not be used in eq 1, meaning that
C1 = C2 = D1 = D2 = 0. The model indicates that the
pseudoequilibrium disposition of the studied compounds was
not aﬀected by metabolism, which could be either negligible or
similar for all compounds.
The internal pH value in terms f1 and f 2 (eq 12) was
optimized as pH 7.56 ± 0.32. This high value can normally be
encountered only in one part of the cell: in the matrix of
mitochondria. Therefore, the ﬁt indicates that the hypothetical
receptors are localized in the bilayer that is in contact with the
mitochondrial matrix. This indication agrees with the current
knowledge about antimycin A’s mechanism of action, which
focuses on inhibition of electron transport.
57,66−69 Antimycin A
binds at the ubiquinone binding site Qi of the complex that is
located on the matrix side of the cristae membrane.
70
Notably, the disposition function provides clear guidelines
for the optimization of the drug structure for the best
Figure 7. Dependence of the pseudoequilibrium, membrane-based DF
on lipophilicity and acidity, as given by the disposition part of eq 1
with the optimized coeﬃcient values listed in the text. The data for
best binders with poor disposition (compounds 17 and 18, Table 1)
are shown as open points.
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log P and pKa values that lead to the maximum drug disposition
in the receptor surroundings. The region of the maximum
disposition can be deﬁned as pKa ≤ log P for log P ≤ 6 and pKa
≤ 6 for log P>6. The knowledge of suitable combinations of
log P and pKa values provides unique clues for optimization of
drug structure, also because the lower log P and pKa values will
lead to increased aqueous solubility.
Factoring Bioactivity into Aﬃnity and Disposition
Components. Equation 1 deﬁnes two contributions to the
aﬃnity: log K (the ﬁrst term) and disposition (log DF; the
remaining terms). The two contributions were enumerated
from the calibrated DF-MSMM CoMFA model (eq 1 and the
accompanying text, Table 3), summarized in Table 1, and
plotted against the experimental antiﬁlarial activities (Table 1)
in Figure 8.
Figure 8 and Table 1 show that two weakly active
compounds (17 and 18) are actually the best binders, which
are held back by poor disposition. Their disposition can be, in
principle, increased by 4−5 logarithmic units, leading to overall
bioactivities approaching log(1/EC50) ≈ 9.5, which is almost 2
orders of magnitude better than that of the most active
compound 7. Disposition is easier to optimize than binding
because the former depends on lipophilicity and acidity, which
are well understood in terms of drug structure. The DF-
MSMM CoMFA model, and cell-QSAR models in general,
provides unique clues for optimization of the compounds.
■ CONCLUSIONS
The cell-QSAR concept adapts ligand-based and receptor-based
3D-QSAR approaches for use with the bioactivities measured in
cells or more complex systems. The adaptation consists of the
extension of the correlation equation speciﬁc for the given 3D-
QSAR method by the DF. The DF describes changes in the
concentration of compounds in the receptor surroundings
originating from membrane accumulation, binding to non-
receptor proteins, hydrolysis, and possibly other processes. The
cell-QSAR concept was used here with the popular ligand-
based CoMFA method. A conceptual combination of the DF
with our MSMM extension of the CoMFA model was applied
to antiﬁlarial activities of antimycin A analogues, representing a
part of the diﬃcult-to-model Selwood data set that is often used
as a test case for assessment of new variable-selection
algorithms. The ﬁtting results are very satisfactory and show
that each component of the model (DF, MS, MM) improves
the predictive ability. The optimized form of the disposition
function indicates that the compounds bind to the hypothetical,
membrane-bound receptor in the cristae bilayer of mitochon-
dria and the diﬀerences in their metabolic rates are negligible.
The perceived complexity of the Selwood data set may be
explained by the nonlinearity of the model in lipophilicity and
acidity in combination with the lack of proper descriptors for
acidity in the original set, the peculiar intramolecular H-bonds
in the salicylamide moiety that diﬀer for neutral and ionized
species, and the structure-speciﬁc receptor binding. The results
also illustrate the utility of the cell-QSAR approach in medicinal
chemistry. Speciﬁcally, the cell-QSAR approach delineates the
aﬃnity and disposition contributions to bioactivity, which
provide for a straightforward, separate structure optimization
for aﬃnity and disposition. Although further testing is
necessary, the cell-QSAR concept seems to be a promising
direction in the structure-based or ligand-based predictions of
bioactivities in cellular or more complex systems and drug
structure optimization. For larger and more diverse data sets,
better superposition techniques and methods for prediction of
species fractions will be necessary. The model-based nature
opens the cell-QSAR concept for incorporation of any future
improvements in 3D-QSAR techniques and the disposition
function, as well as new pharmacology and pharmacodynamic
scenarios.
■ METHODS
Pharmacokinetics (PK), Pharmacology (PL), and Pharmaco-
dynamics (PD) Phases of the Drug Eﬀect in QSAR. The PK phase
is described by the DF. The simplest PL/PD scenario consists of a
situation when the PL phase is represented by the 1:1, fast, and
reversible ligand−receptor interaction and the PD phase describes the
biological eﬀect, which is a direct and immediate consequence of the
drug−receptor interaction and is proportional to the fraction of
occupied receptors. The ligand−receptor association constant K is
deﬁned using the concentrations (denoted by square brackets) of the
ligand (L), receptor (R), and complex (LR) as K = [LR]/([L][R]). In
a cellular system, the free ligand concentration [L] varies because of
the disposition, and consequently, all three concentrations are time-
dependent. Usually, the concentrations are suﬃciently low to
approximate activities. If the concentration of the free receptors [R]
is expressed as the diﬀerence between the total receptor concentration
[R]0 and [LR], the fraction of occupied receptors is given as [LR]/
[R]0 = K[L]/([L] + 1) = E/Emax. The latter equality comes from the
simplest PD phase, describing the primary eﬀect E as being
proportional to the fraction of occupied receptors, [LR]/[R]0.
Secondary eﬀects lacking this simple tie to the receptor modiﬁcation
require more complex PD models.
71 Nevertheless, the above scenario
applies to many drug eﬀects caused by competitive enzyme inhibition
or receptor binding. Since the receptor-bound drug represents only a
small drug fraction in the body, the disposition is not signiﬁcantly
aﬀected by the receptor binding, and the ligand concentration in the
receptor surroundings, [L], can be expressed using the DF with
properties p and time t as variables and the initial ligand concentration
c0:
72
= ptc [L] DF( , ) 0 (2)
To obtain a PK/PL/PD expression, [L] in the above expression for
E/Emax is replaced by the product DF(p,t) cX(t), where cX(t) are the
isoeﬀective drug concentrations eliciting the eﬀect, which is equal to
the fraction X of the maximum eﬀect. With E/Emax = X, the bioactivity,
characterized by cX(t), is described as
72
Figure 8. Dissection of aﬃnity (log K; red symbols) and disposition
(log DF; blue symbols) contributions to overall bioactivity by the
calibrated DF-MSMM CoMFA model. Stars mark the best binders 17
and 18 with poor disposition. All data are given in Table 1.
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Equivalent PK/PL/PD dependencies were derived for the irreversible
drug−receptor interactions, either single or preceded by a fast,
reversible step.
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Equation 3 and equivalent PK/PL/PD relationships provide the
blueprint for a conceptual combination of the disposition function
with any ligand-based or receptor-based 3D-QSAR method for
prediction of binding aﬃnities. The K term in eq 3 needs to be
replaced by a suitable conceptual 3D-QSAR correlation equation, and
the disposition function can be selected from the available
repertoire.
30,32 This cell-QSAR concept represents the recipe for the
formulation of conceptual QSARs for cell-based assays and other
complex systems.
Multispecies Multimode Equilibria. Studied antimycin ana-
logues ionize under the conditions of the experiments, and each
species forms diﬀerent intramolecular H-bonds. The molecules are
ﬂexible, and each species can bind to the receptor R in diﬀerent
orientations or conformations (modes). The generalized multispecies
multimode binding equilibria are outlined in the following equation:
Each binding equilibrium is characterized by the microscopic
association constant Kijk (eq 5) and represents the receptor
binding of the ith ligand in the jth species and the kth binding
mode. In principle, the number of species s and the number of
binding modes m can diﬀer for individual ligands. In the studied
case, there are only two species (s = 2, nonionized and ionized,
with charges 0 and −1, respectively) for each ligand (Table 1).
The number of modes is unknown, since there is no
experimental information available on either the receptor or
the complex, and can diﬀer for individual ligands. In the general
expressions, s and m represent the maximum numbers of
species and binding modes for the tested ligands. The missing
species or modes of some ligands will have zero fractions fij or
zero association constants Kijk (see below).
The microscopic association constant for the ith molecule’s jth
species in the kth binding mode is
= K
[LR ]
[L ][R]
ijk
ijk
ij (5)
Usually, only the total association constant of the ith ligand (Ki)i s
determined, although the microscopic association constants Kijk are the
relevant quantities to be correlated with the structure. To obtain a
conceptual correlation equation for Ki, it must be expressed as a
function of Kijk.
The experimentally measured Ki reﬂects the total concentration of
the ligand/receptor complexes in any species and any binding mode. A
series of rearrangements to the deﬁnition of Ki provides the desired
function of Kijk, shown in eq 6: (1) the total concentration of the
complex [LRi] is expressed as the sum of bound concentrations of
individual species, (2) each summand is formally multiplied by [Lij]/
[Lij] to introduce the fraction of each species, fij =[ L ij]/[Li], and (3)
the bound concentration of each species [LRij] is broken down to
individual binding modes. The relationship between the microscopic
and total association constants is obtained by expressing the m-
summands in eq 6 using eq 5:
∑∑ =
==
Kf K i
j
s
ij
k
m
ijk
11 (7)
Here fij is the fraction of the jth molecular species in the ith compound
in solution. For compounds present in the solution as one species, the
right-hand side of eq 7 is equal to the k-summation. In this case, eq 7 is
in accordance with published analyses of formally analogous situations:
the statistical thermodynamic
73 and equilibrium
58,59 treatment of
multimode binding in ligand/protein interactions and kinetic analyses
of a reversible unimolecular reaction leading to diﬀerent products
74 or
isomers.
75 The expressions for the fractions fij of the jth species can be
derived from the deﬁnition of the ionization constants.
Only one molecule of a compound, in any species and any mode,
can be bound in each complex. The distribution of species and modes
in the bound state is characterized by their prevalences. For the kth
mode of the jth bound species for the ith compound, the prevalence is
== ≈
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The numerator and denominator come from eqs 5 and 6, respectively.
The third quasi-equality ensures that the sum of all s × m prevalences
equals unity. The prevalence of the jth bound species in all modes and
the prevalence of the kth bound mode in all species can easily be
calculated using eq 8.
For the application in CoMFA, eq 7 needs to be logarithmized and
the log Kijk values must be replaced by the correlation equation for
CoMFA:
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Here Cl are the regression coeﬃcients characterizing the weights of the
ligand−probe interaction energies X in individual cross-sections of a
grid surrounding the superimposed ligands. The subscripts indicate the
relatedness to the ith compound, jth species, kth mode, and lth grid
point, and g is the total number of grid points. Other contributions to
the binding free energy (internal ligand energy, binding entropy,
desolvation) can be added to the summation in the exponents. In this
case, we only used the CoMFA energies because the size of the used
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coeﬃcients.
Intracellular Disposition. The pseudoequilibrium DF expresses
the time course of the concentration of nonionized ligand molecules in
the aqueous phases of the studied biosystem during the elimination
period:
=
+
β
−+ + ββ
pt
AP B
DF( , )
1
e
CP D t AP B () / ()
(10)
Here P is the reference partition coeﬃcient, β is the empirical
Collander coeﬃcient, and t is the exposure time. The terms A, B, C,
and D characterize the key fate-determining processes the ligand
molecules undergo in the biological system: A, accumulation in
membranes/protein binding; B, distribution in aqueous phases; C,
lipophilicity-dependent elimination; D, lipophilicity-independent elim-
ination. For the receptors localized in the bilayer, eq 10 needs to be
multiplied by Pβ.
If compounds are present in the aqueous phase in the receptor
surroundings in s species created by ionization, tautomerism, or
carbonyl hydration, the model suggests that each of the parameters A,
B, C, and D (represented by Y) from eq 10 be expanded as
76
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The fractions f of individual species are the same quantities as in eq 9,
except the subscripts i, indicating the compound, are omitted. The
subscripts j denote, as in eq 9, the quantities associated with the jth
species. The fractions of nonionized, neutral molecules (subscript j =
1) and ionized molecules with an overall charge of −1 (subscript j =2 )
are given by the deﬁnition of the dissociation constant Ka for the given
pH of the medium and can be written, respectively, as
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Generally, on the basis of the probable intracellular localization of
the receptors, a reasonable intracellular pH range is 5−8, the lower
limit being observed in lysozomes and the upper limit in the
mitochondrial matrix. The pH value of the cultivation medium could
aﬀect these values, but the exact pH of the assay was not published.
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For this reason and because the receptor localization is unknown, the
pH value in eq 12 was treated as one of the adjustable coeﬃcients.
Data Set. The Selwood data set includes in vitro ﬁlaricidal activities
against D. viteae of 31 antimycin analogues (Table 1), which were
determined by monitoring the leakage of incorporated radiolabeled
adenine from intact female D. viteae after 120 h of exposure.
36,52 The
EC50 values for adenine leakage were calculated after 120 h of exposure
to a range of drug concentrations at 37 °C under neutral conditions.
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The 1-octanol/water partition coeﬃcients P were calculated by the
ClogP program in Bio-Loom
51 software for neutral molecules and are
summarized in Table 1. The values diﬀer from the original data
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because of the developments in the ClogP software. The diﬀerences
are within ±0.25 log unit, except for compounds 6 (Table 1, log Pold −
log Pnew = 1.526), 10 (−0.770), 12 (−0.638), 14 (−1.654), and 26
(0.325). The log P values were used with the belief that they properly
reﬂect the relative lipophilicity of the studied compounds, although the
values of log P>7 were marked in the ClogP output as unrealistically
high. Ionization decreases the log P values by several units, and most
compounds were present mainly as ionized species under physiologic
conditions.
Our multispecies approach can take into account tautomers and
hydrates of aldehydes and ketones; hence, formation of these species
was examined using the SPARC Web server
50 and was found
negligible for all compounds on the basis of the following reasoning.
As shown in eq 7, the binding contribution of each species is given
by the product of the association constant Kij (represented by the sum
of the association constants Kijk for individual modes
61) and the
species fraction fij. The fraction limit for a species to be included in the
correlation was set to 10−4 on the basis of the following considerations.
The interaction of a rare species with the receptor can release about
2−3 kcal/mol more free energy than that of the prevalent species
because both species bind by weak interactions and diﬀer in a single,
well-deﬁned structural feature. For this situation, the product fijKij for
the rare species would be less than 1% of the same quantity for the
prevalent species.
Superposition. Pharmacophore models were built using the
Galahad procedure
54,55 in Sybyl-X. The ligands are ﬁrst aligned ﬂexibly
to each other in torsional space, and then the conformations produced
are rigidly aligned in Cartesian space. Pharmacophore and steric
bitmaps (TUPLET
78) representing H-bonding and steric terms,
respectively, along with the total ligand energy, serve as input to a
multiobjective ﬁtness function. Produced pharmacophores indicated
that the salicylamide moieties of all compounds in all species are
superimposed in all cases. In the absence of structural and other
information on the receptor, the most active and, at the same time,
one of most rigid analogues, compound 7 (Figure 2, Table 1), was
selected as the template for superposition.
Conformational analysis was performed using the Tripos force ﬁeld
in Sybyl
79 with an increment of 10° for all considered torsions. When
the molecule forms an intramolecular H-bond (Figure 1), either as a
neutral species (OH···OC) or as an ionized species (NH···O−), the
ﬁrst torsion Φ1 is ﬁxed and only Φ2, Φ3, and Φ4 are allowed to rotate
in conformational analysis. In the opposite case, when analogues have
no intramolecular H-bond, all four torsions in Figure 2 are considered
rotatable. The approximate minimum conformations were further
optimized and Mulliken charges were calculated in Jaguar
80 using the
DFT/B3LYP method with a 6-31G** basis set. Charge and spin
multiplicity were entered manually for diﬀerent protonation states. In
this way, the conformations of the template for the superposition were
obtained. Open conformation, the mode without the intramolecular
H-bond has the same optimal geometries for both neutral and ionized
species.
In the MM approach, the user is allowed to enter several possible
bound conformations of the template in one optimization run. The
MSMM approach extends this option to all species which are present
in the solution surrounding the receptor. The four basic template
molecules of compound 7 were superimposed by the atom ﬁt method
in Sybyl (Figure 3a). All studied compounds do not share a common
skeleton; therefore, for each compound, both species in all modes were
superimposed on the templates using the FlexS procedure
65 as
incorporated in Sybyl (Figure 3c). FlexS combines conformational
search with alignment in two steps. First, a base fragment of the ligand
is selected and placed on the template. Second, as the rest of the ligand
parts are incrementally built, torsion angles are perturbed to generate
new conformations, and each conformation is scored for superposition
quality. The obtained conformations of all compounds were
minimized by Jaguar using the DFT/B3LYP method
81 with a 6-
31G** basis set
82,83 with all torsions ﬁxed. The Mulliken charges
84
were calculated for the optimized geometries. The superposition was
repeated, and the resulting conformations were used in the CoMFA
analyses.
Interaction Energies. Steric and electrostatic interaction energies
Xijkl with an sp3 carbon probe with a +1 charge were calculated for each
compound (subscript i) in each species (subscript j) and each binding
mode (skeleton conformations × ring-ﬂipping conformations, sub-
script k). The probe was placed at each lattice intersection (subscript l)
of a 3D grid (2 Å in each coordinate direction). The grid has the
following coordinates: −7 to +18 Å along the x-axis, 1−21 Å along the
y-axis, and −15 to +11 Å along the z-axis. An energy cutoﬀ of 30 kcal/
mol was used to cap the maximum used energies.
Regression Analysis. The correlation equation is obtained by
taking the logarithm of eq 3, in which the association constant log K is
replaced by eq 9 and the disposition function DF(p,t) is given by eq
10, as combined with eq 11, in which the fractions are expressed by eq
12. The receptor-binding and disposition components have, from the
optimization viewpoint, quite diﬀerent properties: eq 9 has only one
form, and the descriptive variables need to be selected from a large
pool, while eqs 10−12 contain only two variables, which are organized
in one of two possible functional forms, depending upon the location
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receptor-binding part (eq 9), the coeﬃcients Cl are associated with the
grid points and are independent of the species and modes. Therefore,
the ﬁnal set of optimized coeﬃcients is independent of the numbering
of individual species and modes. Notably, the inclusion of multiple
species and multiple modes does not increase the number of optimized
regression coeﬃcients Cl.
The correlation equation is nonlinear in the coeﬃcients Cl in eq 9
and the coeﬃcients A−D, pH and β in eqs 10−12. All statistical
procedures
61 were written in C programming language and integrated
in Sybyl through the Sybyl Programming Language (SPL) scripts. The
choice of one of the two implemented optimization methods depends
on the total number (N) of coeﬃcients C in the calibrated model and
on the number of compounds (n). Nonlinear regression analysis is
applied when N ≤ n/2. Otherwise, the developed software
automatically switches to the PLS analysis with a linearized form
61
of eq 9. The second option was not used for optimization of the best
models. Both optimization methods are sensitive to good initial
estimates. Therefore, a forward-selection procedure, conceptually
similar to that used before for multimode analysis,
61 was a rational
choice.
Before analysis, the Xijkl variables (energy columns) were sorted
using the following criteria: (1) high and sustained variability, (2) the
minimal number of colinear columns with similar information, and (3)
even distribution of selected grid points around the ligands. Sustained
variability means that the energy values cover the whole interval more
or less evenly and are not clustered. An extreme case is the situation
when all energies in a given column are equal (usually zero) and only
one mode has a diﬀerent energy. These singularities originate when
only one molecule protrudes into a subspace and other molecules do
not aﬀect the probe interaction energies in that subspace. Singular
molecules need to be eliminated from the analysis because they do not
provide statistically signiﬁcant information about the poorly covered
subspace.
The model calibration can be steered by user-deﬁned inputs, for
which the default values are shown in parentheses. The process starts
with a quick scan through the models consisting of a few (four)
variables which are randomly selected from the top variables (10%).
The initial values of the coeﬃcients (±0.1) are systematically evaluated
by a grid search. In this step, no optimization is applied and the
correlation equation is evaluated for the initial coeﬃcients. For the
best models (top 10% r2), the coeﬃcients are optimized. At each of the
following steps, a reduction of the number of coeﬃcients is attempted:
the coeﬃcients, which do not lead to a decrease in the r2 value, are
eliminated. The best models (top 5% r2) are developed by a gradual
addition of groups of a few (three) variables until all variables from the
selected set (top 10%) are used. The procedure is ﬁnalized by ﬁne-
tuning of the best models (top 5% r2) by addition of single variables.
The best model is selected on the basis of the following criteria: N, r2,
q2 for the leave-one-out cross-validation (applied to the training set
only to eliminate unstable models), and the standard errors of the
parameters.
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